105,528 Shares in Pharvaris N.V. $PHVS Purchased by ADAR1 Capital Management LLC

Key Points

• ADAR1 Capital Management acquired 105,528 Pharvaris shares worth approximately $3.65 million, representing a 0.16% stake. Several other institutional investors also initiated or increased positions.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $51.08, although two firms maintain sell ratings.
• Pharvaris shares opened at $37.23 after the company reported a quarterly loss of $0.81 per share, missing estimates by $0.06; insiders have sold 121,325 shares worth about $4.27 million over the past 90 days.

ADAR1 Capital Management LLC acquired a new stake in Pharvaris N.V. (NASDAQ:PHVS - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The fund acquired 105,528 shares of the company's stock, valued at approximately $3,649,000. ADAR1 Capital Management LLC owned 0.16% of Pharvaris as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in PHVS. Quantbot Technologies LP purchased a new stake in shares of Pharvaris during the 2nd quarter valued at approximately $41,000. JPMorgan Chase & Co. lifted its position in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock worth $59,000 after acquiring an additional 783 shares in the last quarter. Barclays PLC purchased a new stake in shares of Pharvaris during the fourth quarter worth $77,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Pharvaris in the fourth quarter worth $86,000. Finally, CoreCap Advisors LLC bought a new position in shares of Pharvaris in the second quarter worth $93,000.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Wells Fargo & Company assumed coverage on Pharvaris in a research report on Wednesday, July 15th. They set an "overweight" rating and a $55.00 target price for the company. Morgan Stanley raised their price target on Pharvaris from $41.00 to $46.00 and gave the company an "overweight" rating in a report on Thursday, June 25th. HC Wainwright reiterated a "buy" rating on shares of Pharvaris in a research report on Friday, August 14th. Wall Street Zen cut shares of Pharvaris from a "hold" rating to a "sell" rating in a research report on Saturday, July 18th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pharvaris in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $51.08.

Insider Activity at Pharvaris

In other Pharvaris news, insider Anne Lesage sold 30,703 shares of the company's stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total value of $1,089,649.47. Following the completion of the transaction, the insider directly owned 93,969 shares in the company, valued at approximately $3,334,959.81. This represents a 24.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Berndt Modig sold 2,292 shares of the firm's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $34.77, for a total transaction of $79,692.84. Following the completion of the sale, the chief executive officer directly owned 130,625 shares of the company's stock, valued at approximately $4,541,831.25. This represents a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 121,325 shares of company stock valued at $4,270,425 in the last 90 days.

Pharvaris Stock Down 0.2%

Shares of Pharvaris stock opened at $37.23 on Wednesday. The company's fifty day simple moving average is $34.40 and its two-hundred day simple moving average is $30.56. Pharvaris N.V. has a 12-month low of $20.65 and a 12-month high of $38.13. The firm has a market cap of $2.44 billion, a PE ratio of -12.21 and a beta of -2.31.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). As a group, sell-side analysts expect that Pharvaris N.V. will post -3.15 earnings per share for the current fiscal year.

Pharvaris Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

Want to see what other hedge funds are holding PHVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pharvaris N.V. (NASDAQ:PHVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source